Virtus Advisers LLC Acquires 12,091 Shares of Vericel Corporation $VCEL

Virtus Advisers LLC increased its holdings in shares of Vericel Corporation (NASDAQ:VCEL – Free Report) by 77.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,661 shares of the biotechnology company’s stock after buying an additional 12,091 shares during the period. Virtus Advisers LLC’s holdings in Vericel were worth $1,110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. MCF Advisors LLC increased its holdings in Vericel by 293.0% in the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 583 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in Vericel during the second quarter worth $36,000. Allworth Financial LP acquired a new position in Vericel during the second quarter worth $60,000. Integrated Wealth Concepts LLC purchased a new position in Vericel during the second quarter valued at $72,000. Finally, GAMMA Investing LLC lifted its holdings in Vericel by 17.7% during the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 283 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on VCEL shares. Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a research report on Thursday, July 30th. HC Wainwright boosted their target price on shares of Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Wall Street Zen upgraded shares of Vericel from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. TD Cowen raised their price target on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Truist Financial raised their price target on shares of Vericel from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Vericel has a consensus rating of “Buy” and a consensus price target of $62.00.

Get Our Latest Stock Analysis on Vericel

Vericel Price Performance

NASDAQ VCEL traded down $0.46 during mid-day trading on Friday, hitting $56.96. The stock had a trading volume of 698,761 shares, compared to its average volume of 911,978. The firm’s 50 day moving average is $42.78 and its 200 day moving average is $39.41. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $59.75. The stock has a market capitalization of $2.91 billion, a price-to-earnings ratio of 89.00 and a beta of 1.08.

Vericel (NASDAQ:VCEL – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The company had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. During the same quarter last year, the firm posted $0.10 EPS. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. As a group, equities research analysts expect that Vericel Corporation will post 0.78 earnings per share for the current year.

Insider Buying and Selling at Vericel

In other news, Director Robert L. Md Zerbe sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $57.88, for a total value of $115,760.00. Following the transaction, the director directly owned 32,995 shares of the company’s stock, valued at approximately $1,909,750.60. This trade represents a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Jonathan Siegal sold 1,500 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $52.90, for a total transaction of $79,350.00. Following the completion of the transaction, the insider directly owned 1,259 shares in the company, valued at approximately $66,601.10. This represents a 54.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 49,008 shares of company stock worth $2,701,078 over the last three months. 7.60% of the stock is owned by corporate insiders.

Vericel Company Profile

(Free Report)

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

Featured Stories

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL – Free Report).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.